Food al­ler­gy biotech gets $50M loan; Sean Ianchulev’s med­ical de­vice com­pa­ny rais­es a $23M Se­ries B

Al­ladapt Im­munother­a­peu­tics put out word on Tues­day that it has en­tered in­to a term loan agree­ment with Her­cules Cap­i­tal for up to $50 mil­lion.

Ac­cord­ing to the biotech, which fo­cus­es on IgE-me­di­at­ed food al­ler­gies, this new in­jec­tion of cap­i­tal will be used to sup­port the clin­i­cal de­vel­op­ment of Al­ladapt’s lead as­set, ADP101, through the ini­ti­a­tion of a Phase III tri­al, as well as the com­ple­tion of its man­u­fac­tur­ing fa­cil­i­ty in­tend­ed for the clin­i­cal sup­ply of the can­di­date and a po­ten­tial com­mer­cial prod­uct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER